At‐Home Self‐Collection of Pharmacokinetic Data: Design and Results From a Phase 1 Open‐Label Feasibility Trial
2024

At-Home Self-Collection of Pharmacokinetic Data

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): Arash Raoufinia, Susan E. Shoaf, Brian Rothman, Chelsea Ye, Chris Chung

Primary Institution: Otsuka Pharmaceutical Development & Commercialization Inc.

Hypothesis

Can participants accurately collect pharmacokinetic data at home compared to staff collection?

Conclusion

The study shows that participants can successfully collect pharmacokinetic samples, ECGs, and vital signs at home with proper training.

Supporting Evidence

  • At least 75% of participants obtained blood microsamples within 10 minutes of the planned time.
  • No adverse events were related to treatment.
  • Participants successfully conducted safety assessments remotely.
  • Mean absolute differences in sample collection times were small, indicating accuracy.
  • Participants were trained to use mobile medical devices for data collection.

Takeaway

This study found that people can take their own medical samples at home, which can make it easier for them to join medical studies.

Methodology

A Phase 1, open-label, fixed-sequence trial where participants collected pharmacokinetic samples, ECGs, and vital signs at home after taking centanafadine.

Potential Biases

Participants who are more likely to participate may not represent the general population.

Limitations

The trial may be subject to bias due to self-selection of participants.

Participant Demographics

Healthy adults aged 18-55 years, with a mean age of 35.9 years, and 90% female.

Digital Object Identifier (DOI)

10.1002/cpdd.1495

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication